

Form Title Buprenorphine/Naloxone (Suboxone®) Initiation Emergency Department,

Adult Orders

Form Number 21289-bond

© 2018, Alberta Health Services, CKCM



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

To view a copy of this license, visit

https://creativecommons.org/licenses/by-nc-nd/4.0/

Disclaimer: This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.



Buprenorphine/Naloxone (Suboxone®) Initiation Emergency Department, Adult Orders Set

Select orders by placing a (✓) in the associated box

Last Name (Legal)		First Name (Legal)		
Preferred Name 🗆 La	referred Name □ Last □ First		DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X) ☐ Unknown				

The Opioid Use Disorder Telephone Consultation Line is available 0800-2000 hours daily including weekends and statutory holidays

Ensure ALL three inclusion criteria met:

- Age 18 years old and older. If the patient is under the age of 18, consider calling the Opioid Use Disorder Telephone Consultation Line OR discuss with an Addictions and/or Pediatric consultant.
- Suspicion of opioid use disorder
- Patient willing to engage in buprenorphine/naloxone

Exclusion Criteria

- Allergy to buprenorphine or naloxone
- Being admitted for medical/psychiatric concern
- Severe liver dysfunction
- Currently prescribed or using methadone or buprenorphine/naloxone
- Clinical signs of sedative/depressant impairment or intoxication (*DO NOT use EtOH level in isolation)

Priority

☐ Provide naloxone kit and associated teaching at soonest opportunity

Pregnancy

Pregnant patients ARE NOT EXCLUDED from taking buprenorphine/naloxone but will likely benefit from expert consultation or opinion to guide dosing, other management considerations, and follow-up. Opiate withdrawal is a risk to the fetus and may increase the risk of spontaneous abortion / premature labour, or other complications. Consider calling the Opioid Use Disorder Telephone Consultation Line or discuss with the OB-GYN consultant on call or providing consultation.

Prior to initiating buprenorphine/naloxone

1. Determine TIME since LAST opioid use:

- Initiate buprenorphine/naloxone at least 12 hours since last Short Acting Opioid (e.g. fentanyl, heroin, crushed OxyContin®, Percocet®)
- Initiate buprenorphine/naloxone at least 24 hours since last Long Acting Opioid (e.g. PO OxyContin®, Hydromorph Contin®, OxyNeo®)
- Initiate buprenorphine/naloxone at least 72 hours since last methadone dose

2. Determine initial Clinical Opiate Withdrawal Scale (COWS) score:

Patient Care

Patient Care Assessments

☐ Perform Clinical Opiate Withdrawal Scale (COWS) score now. See form 20900.

IF, sufficient time since last opioid use AND COWS score greater than or equal to 12 →

Continue to ED INDUCTION orders

IF, insufficient time since last opioid use and/or COWS score less than 12 \rightarrow

Continue to HOME INDUCTION order					
Date (dd-Mon-yyyy)	Time (hh mm)				

21289Bond(Rev2020-03) Page 1 of 3



Buprenorphine/Naloxone (Suboxone®) Initiation Emergency Department, Adult **Orders Set**

S

Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X) ☐ Unknown				

Select o	rders by placing a (✓) in the associated bo	X □Non-binary/Prefer not to disclose (λ	⟨) □ Unknown			
Emergency Department Induction Orders						
Patien	t Care					
Patient	Care Assessments					
	Perform Clinical Opiate Withdrawal Scale (COWS) score prior to first dose and then once again after 1 hour. See form 20900.					
	Inform MD if signs of precipitated withdrawal (Patient complaining of marked worsening symptoms of opioid withdrawal within 30 minutes of the first dose of buprenorphine/naloxone)					
	One hour after second buprenorphine/naloxone dose, inform MD for possible patient discharge					
Medic	ations					
Central	Nervous System Agents					
IF suffic	ient time since LAST opioid use AND Clinical Opio	ate Withdrawal Scale (COWS) is greater	than or equal to 12,			
	□ buprenorphine/naloxone 2 mg/0.5 mg SL 1 tab sublingually once witnessed. Dose 1 to be given only if sufficient time since LAST opioid use AND Clinical Opiate Withdrawal Scoring (COWS) score is greater than or equal to 12. Nurse to observe all buprenorphine/naloxone doses to ensure taken sublingually and tablet dissolves. Patient to stay NPO for 30 minutes after tablet dissolves.					
AND ⁻	ΓHEN,					
Reasse	Reassess Clinical Opiate Withdrawal Scale (COWS) after 1 hour, if NO signs of precipitated withdrawal, give:					
	buprenorphine/naloxone 2 mg/0.5 mg SL 2 to be given only if at 1 hour following dose 1, NO signs of precipitated withdrawal. Nurse to taken sublingually and tablet dissolves. Patie	COWS remains same or improves a observe all buprenorphine/naloxone	and patient shows e doses to ensure			
Disch	arge Instructions/Follow Up					
After the second dose is given, provide 3 additional doses for patient to take home.						
	buprenorphine/naloxone 2 mg/0.5 mg SL 1 to 3 tabs to be dispensed for patient to take hor	- · · · · · · · · · · · · · · · · · · ·				
	☐ Provide and give Emergency Department Buprenorphine/Naloxone Initiation Patient Information					
	Sheet: Discharge Instructions.					
	 □ Confirm discharge counselling done as per Patient Information Sheet by MD and nurse. □ Patient to return to ED if symptoms acutely worsen or feel unable to manage. □ Provide naloxone kit and associated teaching to patient at soonest convenience. Review harm reduction practices: use clean supplies, do not use drugs alone, use smaller test doses if still using, provide information for supervised consumption sites. 					
	□ Confirm Fax/Referral Sheet sent to Opioid Use Disorder Treatment Clinic. Patient provided					
	information for follow-up appointment.					
Prescri	ber Signature	Date (dd-Mon-yyyy)	Time (hh mm)			

Page 2 of 3 21289Bond(Rev2020-03)



Buprenorphine/Naloxone (Suboxone®) Initiation Emergency Department, Adult Orders Set

Select orders by placing a (\checkmark) in the associated box

Last Name (Legal)		First Name (Legal)		
Preferred Name □ L	.ast □ First DO		DOB	(dd-Mon-yyyy)
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Non-binary/Prefer not to disclose			se (X)	☐ Female ☐ Unknown

Home Induction Orders						
Patient Care						
Patient Care Assessments						
☐ Perform initial Clinical Opiate Withdrawal	Scale (COWS) score. See form 2090	0.				
Medications						
Central Nervous System Agents						
IF insufficient time since LAST opioid use and/or Clinical	Opiate Withdrawal Scale (COWS) is less	than 12 in the				
emergency department, give the following medication to t	ake home:					
☐ buprenorphine/naloxone 2 mg/0.5 mg SL 6 tabs to be dispensed for patient to take I						
Discharge Instructions/Follow Up						
Ensure 6 tabs dispensed for patient to take home.						
 Provide and give Emergency Department Buprenorphine/Naloxone Initiation Patient Information Sheet: Home Dosing Information. 						
☐ Confirm discharge counselling done as pe	r Patient Information Sheet by MD an	ıd nurse.				
☐ Patient to return to ED if symptoms acutel	☐ Patient to return to ED if symptoms acutely worsen or feel unable to manage.					
 Provide naloxone kit and associated teaching to patient at soonest convenience. Review harm reduction practices: use clean supplies, do not use drugs alone, use smaller test doses if still using, provide information for supervised consumption sites. Confirm Fax/Referral Sheet sent to Opioid Use Disorder Treatment Clinic. Patient provided information for follow-up appointment. 						
Prescriber Signature Date (dd-Mon-yyyy) Time (hh mm)						

21289Bond(Rev2020-03) Page 3 of 3